QR Kodea

A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance

BackgroundMET proto-oncogene amplification (amp) is an important mechanism underlying acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). However, the optimal treatment strategy after acquiring MET-amp-mediated EGFR-TKI resistance remains controversial....

Deskribapen osoa

Gorde:
Egile Nagusiak: Li Liu, Jingjing Qu, Jianfu Heng, Chunhua Zhou, Yi Xiong, Haiyan Yang, Wenjuan Jiang, Liang Zeng, Songlin Zhu, Yongchang Zhang, Jiarong Tan, Chengping Hu, Pengbo Deng, Nong Yang
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Frontiers Media S.A. 2021-10-01
Saila:Frontiers in Oncology
Gaiak:
EGFR mutation
MET amplification
EGFR-TKI and crizotinib combination
NSCLC
EGFR-TKI resistance
Sarrera elektronikoa:https://www.frontiersin.org/articles/10.3389/fonc.2021.722039/full
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak